...
search icon
cgem-img

Cullinan Oncology LLC Share Price

CGEM
NSQ
$11.69
-$0.27
(-2.26%)
1D
Industry: Biotechnology Sector: Health Care

Cullinan Oncology LLC Analyst Forecast

Cullinan Oncology LLC Share Price Chart

Cullinan Oncology LLC Key Stock Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$706.55M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
339.46K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
-0.10
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$5.68 L
$13.43 H
$11.69

About Cullinan Oncology LLC, Common Stock

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. The company develops zipalertinib, a bioavailable small molecule in Phase 3 trial for the treatment of patients with non-small cell lung cancer; CLN-978, a T cell engager to treat systemic lupus erythematosus and rheumatoid arthritis; and CLN-619, a monoclonal antibody in Phase 1 trial for the treatment of solid tumors and multiple myeloma. Its development products also include CLN-049, a humanized bispecific antibody in Phase 1 trial for the treatment of acute myeloid leukemia (AML) or myelodysplastic syndrome, as well as measurable residual disease positive AML; and CLN-617, a fusion protein in Phase 1 trial for the treatment of solid tumors. It has a collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop zipalertinib. The company was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Cullinan Oncology LLC Stock Returns

Time FrameCGEMSectorS&P500
1-Week Return0.93%0.91%2.13%
1-Month Return12.72%-0.72%-0.47%
3-Month Return43.23%2.24%1.29%
6-Month Return64.51%19.1%7.71%
1-Year Return20.93%7.15%14.7%
3-Year Return8.24%16.96%67.75%
5-Year Return-70.1%33.23%76.25%
10-Year Return-60.01%142.74%271.83%

Cullinan Oncology LLC Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue18.94M18.94M---[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Cost of Revenue62.00K53.00K93.00K310.00K306.00K[{"date":"2020-12-31","value":20,"profit":true},{"date":"2021-12-31","value":17.1,"profit":true},{"date":"2022-12-31","value":30,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":98.71,"profit":true}]
Gross Profit(62.00K)18.94M(93.00K)(310.00K)(306.00K)[{"date":"2020-12-31","value":-0.33,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-0.49,"profit":false},{"date":"2023-12-31","value":-1.64,"profit":false},{"date":"2024-12-31","value":-1.62,"profit":false}]
Gross Margin(0.33%)100.00%(Infinity%)(Infinity%)(Infinity%)[{"date":"2020-12-31","value":-0.33,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false},{"date":"2024-12-31","value":null,"profit":false}]
Operating Expenses60.34M86.90M(144.65M)191.09M196.61M[{"date":"2020-12-31","value":30.69,"profit":true},{"date":"2021-12-31","value":44.2,"profit":true},{"date":"2022-12-31","value":-73.57,"profit":false},{"date":"2023-12-31","value":97.19,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(60.34M)(67.95M)144.65M(191.09M)(196.92M)[{"date":"2020-12-31","value":-41.71,"profit":false},{"date":"2021-12-31","value":-46.98,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-132.11,"profit":false},{"date":"2024-12-31","value":-136.14,"profit":false}]
Total Non-Operating Income/Expense1.76M946.00K13.28M43.49M59.12M[{"date":"2020-12-31","value":2.99,"profit":true},{"date":"2021-12-31","value":1.6,"profit":true},{"date":"2022-12-31","value":22.46,"profit":true},{"date":"2023-12-31","value":73.57,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Pre-Tax Income(59.46M)(67.48M)151.32M(169.22M)(167.46M)[{"date":"2020-12-31","value":-39.29,"profit":false},{"date":"2021-12-31","value":-44.6,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-111.83,"profit":false},{"date":"2024-12-31","value":-110.67,"profit":false}]
Income Taxes(8.61M)(2.44M)42.12M(14.12M)117.00K[{"date":"2020-12-31","value":-20.44,"profit":false},{"date":"2021-12-31","value":-5.8,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-33.53,"profit":false},{"date":"2024-12-31","value":0.28,"profit":true}]
Income After Taxes(50.85M)(65.04M)109.19M(155.10M)(167.57M)[{"date":"2020-12-31","value":-46.57,"profit":false},{"date":"2021-12-31","value":-59.56,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-142.04,"profit":false},{"date":"2024-12-31","value":-153.46,"profit":false}]
Income From Continuous Operations(59.46M)(65.57M)109.19M(155.10M)(167.57M)[{"date":"2020-12-31","value":-54.45,"profit":false},{"date":"2021-12-31","value":-60.05,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-142.04,"profit":false},{"date":"2024-12-31","value":-153.46,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(50.85M)(65.04M)111.21M(153.16M)(167.38M)[{"date":"2020-12-31","value":-45.72,"profit":false},{"date":"2021-12-31","value":-58.48,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-137.72,"profit":false},{"date":"2024-12-31","value":-150.51,"profit":false}]
EPS (Diluted)(4.91)(1.50)2.37(3.69)(3.03)[{"date":"2020-12-31","value":-207.11,"profit":false},{"date":"2021-12-31","value":-63.36,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-155.7,"profit":false},{"date":"2024-12-31","value":-127.85,"profit":false}]

Cullinan Oncology LLC Ratios

Cullinan Oncology LLC Liquidity Ratios

These ratios help you determine the liquidity of the company. Higher is better.

CGEM
Cash Ratio 10.15
Current Ratio 10.45

Cullinan Oncology LLC Asset Efficiency Ratios

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

CGEM
ROA (LTM) -26.53%
ROE (LTM) -40.18%

Cullinan Oncology LLC Liability Ratios

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

CGEM
Debt Ratio Lower is generally better. Negative is bad. 0.07
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.93

Cullinan Oncology LLC Valuation Ratios

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

CGEM
Trailing PE NM
Forward PE 6.30
P/S (TTM) 26.88
P/B 1.57
Price/FCF NM
EV/R 11.55
EV/Ebitda NM

FAQs

What is Cullinan Oncology LLC share price today?

Cullinan Oncology LLC (CGEM) share price today is $11.69

Can Indians buy Cullinan Oncology LLC shares?

Yes, Indians can buy shares of Cullinan Oncology LLC (CGEM) on Vested. To buy

from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CGEM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Cullinan Oncology LLC be purchased?

Yes, you can purchase fractional shares of Cullinan Oncology LLC (CGEM) via the Vested app. You can start investing in Cullinan Oncology LLC (CGEM) with a minimum investment of $1.

How to invest in Cullinan Oncology LLC shares from India?

You can invest in shares of Cullinan Oncology LLC (CGEM) via Vested in three simple steps:

  • Click on Sign Up or Invest in CGEM stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Cullinan Oncology LLC shares
What is Cullinan Oncology LLC 52-week high and low stock price?

The 52-week high price of Cullinan Oncology LLC (CGEM) is $13.43. The 52-week low price of Cullinan Oncology LLC (CGEM) is $5.68.

What is Cullinan Oncology LLC price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Cullinan Oncology LLC (CGEM) is

What is Cullinan Oncology LLC price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Cullinan Oncology LLC (CGEM) is 1.57

What is Cullinan Oncology LLC dividend yield?

The dividend yield of Cullinan Oncology LLC (CGEM) is 0.00%

What is the Market Cap of Cullinan Oncology LLC?

The market capitalization of Cullinan Oncology LLC (CGEM) is $706.55M

What is Cullinan Oncology LLC's stock symbol?

The stock symbol (or ticker) of Cullinan Oncology LLC is CGEM

How Can Investors Use Cullinan Oncology LLC Share Price Data for Long-Term Investment Decisions?

Consider the share price of Cullinan Oncology LLC as a long-term story and not a daily point list. The price represents a movement of the stock in both good and bad times when looked at over many years. This assists the investors to know whether Cullinan Oncology LLC has succeeded to expand steadily and overcome market declines. With this price movement observed and the way the business is progressing, it is easier to make a decision whether the stock is worth having in the long term or not.

How does USD - INR currency movement impact returns from Cullinan Oncology LLC shares for Indian investors?

When investing in Cullinan Oncology LLC shares, you are not based in India then your investment is not just based on the stock price. It is also determined by the currency movement of the dollar in relation to the rupee. When you have an appreciation of the Cullinan Oncology LLC stock and the dollar appreciation is also the same, you gain more in terms of rupees. When the rupee appreciated, it will lower your profits. This currency flow is a silent cause of great contribution to your ultimate returns over many years.

How should investors compare Cullinan Oncology LLC share price with other stocks in the same sector?

Rather than merely checking the share price of Cullinan Oncology LLC and comparing it with that of other stocks in the same sector, one can check how robust the business is. Investors tend to compare such aspects as profits, cash generation, and the stability of the revenues of the company. This means that Cullinan Oncology LLC stock in most cases does not react in the same manner as other companies in the sector due to its brand and services revenue.

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top